Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.

ABSTRACT:

Background

Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness.

Methods

We conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. The primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both. The trial was sto

SUBMITTER: Libster R 

PROVIDER: S-EPMC7793608 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature